Adam Logal
Director of Finance/CFO en OPKO HEALTH, INC. .
Fortuna: 214 997 $ al 31/03/2024
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Steven Rubin | M | 63 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel.
eXegenics, Inc.
| 17 años |
Phillip Frost | M | 87 |
eXegenics, Inc.
| 17 años |
Athena Kartsaklis | F | 59 | 7 años | |
Curtis Lockshin | M | 64 | 13 años | |
Nell Beattie | F | 36 | 9 años | |
Jane Hsaio | M | 77 |
eXegenics, Inc.
| 17 años |
Jeff Baxter | M | 62 | 8 años | |
Jeffrey F. Eisenberg | M | 58 | 8 años | |
Allen Craig | M | - | 6 años | |
John Paganelli | M | 89 |
eXegenics, Inc.
| 21 años |
Roger Medel | M | 77 | 4 años | |
James Eric Callaway | M | 68 | 7 años | |
Nicole Anderson | F | - | 7 años | |
Gary Nabel | M | 70 | 2 años | |
Grigory G. Borisenko | M | 55 | 5 años | |
Michel de Wilde | M | 74 | 8 años | |
Alexey Vinogradov | M | 54 | 5 años | |
Firdaus Jal Dastoor | M | 72 | 10 años | |
Roger Kornberg | M | 77 | 8 años | |
Dmitriy Dmitrievich Genkin | M | 56 | 5 años | |
Richard Krasno | M | 82 | 7 años | |
Richard Pfenniger | M | 68 | 16 años | |
James F. Parslow | M | 59 | 7 años | |
Lin-Tsing Yu | M | 80 | 15 años | |
Prem Lachman | M | 64 | 3 años | |
Elias Zerhouni | M | 72 | 2 años | |
James Weisberger | M | 68 | 21 años | |
Stephen A. Strugnell | M | - | 10 años | |
Elizabeth Nabel | M | 72 | 2 años | |
Moshe Mizrahy | M | 71 | - | |
Steve Schaeffer | M | 73 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 15 años |
Francisco Diaz-Mitoma | M | 69 | 8 años | |
Avi Mazaltov | M | 62 | 7 años | |
David Anderson | M | 54 | 8 años | |
Oren Hershkovitz | M | 47 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 8 años |
Jane Pine Wood | F | 62 | 8 años | |
Laura Moschcovich | M | - |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 4 años |
Victoria Laughman | F | - | - | |
Jane Pine Wood | F | - | - |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Michael Scott Maguire | M | 61 | 3 años | |
Marc Grodman | M | 72 | 35 años | |
Jon Cohen | M | 69 | 3 años | |
Raafat E. F. Fahim | M | 70 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 9 años |
Robert A. Baron | M | 84 |
eXegenics, Inc.
| 14 años |
Warren W. Erdmann | M | - | 22 años | |
Richard Alan Lerner | M | 85 |
eXegenics, Inc.
| 14 años |
Sam Singer | M | 80 | 28 años | |
Subbarao V. Uppaluri | M | 75 |
eXegenics, Inc.
| 5 años |
Jordan I. Siegel | M | 58 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 2 años |
Alexis Borisy | M | 52 | 2 años | |
Anthony Japour | M | 64 | - | |
Scott Requadt | M | 56 | 3 años | |
Peter B. Davis | M | 77 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 6 años |
Dave A. Eichler | M | - |
eXegenics, Inc.
| - |
Michael Reich | M | 81 |
eXegenics, Inc.
| 2 años |
Jason Aryeh | M | 56 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 6 años |
Paul Kessler | M | 69 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 7 años |
Dmitry Yuryevich Kolosov | M | 44 | - | |
Christopher McNulty | M | 47 | 5 años | |
Robert S. Fishel | M | 62 | 4 años | |
Kate Inman | F | - | 6 años | |
Samuel Reich | M | 49 |
eXegenics, Inc.
| 1 años |
Rulfo Hernandez | M | 45 | 7 años | |
Joseph Benincasa | M | 74 | 10 años | |
Mark L. Smith | M | 72 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 7 años |
David J. Gury | M | 85 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 20 años |
John Roglieri | M | 84 | 20 años | |
Howard Dubinett | M | 72 | 34 años | |
Ben Bronstein | M | 74 | 1 años | |
Harry Elias | M | 93 | 11 años | |
Timothy Patrick Lynch | M | 54 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 5 años |
Pascal J. Goldschmidt | M | - | 4 años | |
Gili Hart | M | 49 |
OPKO Biologics Ltd.
OPKO Biologics Ltd. Pharmaceuticals: MajorHealth Technology OPKO Biologics Ltd. develops next-generation, bio-better, long-acting versions of therapeutic proteins and peptide drugs. Its products include Human Growth Hormone, Glucagon dual receptor agonist, Factor VIIa and Factor IX for Hemophilia, Anti-Obesity Peptide Oxyntomodulin, Interferon and Erythropoietin, and Atherosclerosis and Rheumatoid Arthritis long-acting therapies. The company was founded by Novik A. Shai on August 22, 2003 and is headquartered in Nes Ziona, Israel. | 13 años |
Jimmy Wang | M | - | 1 años | |
Patricia Sandler | F | 55 | - | |
Maduri Perri | F | - | 2 años | |
Thomas Nusbickel | M | 67 | 2 años | |
Gregory Henderson | M | - | - | |
Daniel Haines | M | - | 1 años | |
Sam Chawla | M | 49 | 4 años | |
Igor Gitelman | M | 48 | 11 años | |
Juan F. Rodriguez | M | 56 | 2 años | |
Geoff Monk | M | - | - | |
Scott Moomaw | M | 54 | 2 años | |
E. Scott Toner | M | - | 1 años | |
Gordon F. Martin | M | - |
eXegenics, Inc.
| - |
David Okrongly | M | - | - | |
Mitchell Steiner | M | 63 | 2 años | |
Ran Nussbaum | M | 51 | 1 años | |
S. James Freedman | M | 57 | - | |
Melvin D. Rubin | M | - | - | |
Daniel E. Greenleaf | M | 59 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | 1 años |
Melvin L. Rubin | M | - |
eXegenics, Inc.
| - |
Ronald Trust | M | - | - | |
Christine V. Sapan | M | 76 |
Nabi Biopharmaceuticals
Nabi Biopharmaceuticals BiotechnologyHealth Technology Nabi Biopharmaceuticals develops and manufactures biopharmaceutical products. It focuses on the development of vaccines addressing unmet medical needs, including gram-positive bacterial infections and nicotine addiction. The Nicotine Addiction area develops NicVAX, which is an innovative and proprietary investigational vaccine for the treatment of nicotine addiction and prevention of smoking relapse based on patented technology. Nabi Biopharmaceuticals was founded in 1969 and is headquartered in Rockville, MD. | - |
Ilan Kaufthal | M | 76 | - | |
Dale Pfost | M | - |
eXegenics, Inc.
| - |
Thomas E. Beier | M | 78 | - | |
Les Funtleyder | M | 55 | 2 años | |
Jed Fulk | M | 64 | 5 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Estados Unidos | 96 | 96.00% |
Israel | 5 | 5.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Adam Logal
- Red Personal